Login to Your Account



Sonus, Schering In Tocosol Paclitaxel Deal Worth $168M

By Karen Pihl-Carey


Wednesday, October 19, 2005
After starting a pivotal trial last month, Sonus Pharmaceuticals Inc. now has secured a sweet deal for its cancer product Tocosol Paclitaxel, giving exclusive worldwide rights to Schering AG. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription